Why the study?
Does patisiran reduce stroke volume decline and loss of left ventricular compliance in patients with hereditary transthyretin-mediated amyloidosis with cardiac involvement?
Does patisiran reduce stroke volume decline and loss of left ventricular compliance in patients with hereditary transthyretin-mediated amyloidosis with cardiac involvement?
Answers are grounded in this paper and cite their sources.
Non-invasive pressure-volume loop analysis demonstrates that patisiran reduces the loss of left ventricular compliance and stroke volume decline in patients with hereditary transthyretin-mediated amyloidosis.
This article refers to ‘Effect of patisiran on stroke volume in hereditary transthyretin-mediated amyloidosis: insights from pressure–volume analysis of the APOLLO study’ by H.R. Rosenblum et al., published in this issue on pages 727–736. Classically the assessment of cardiac function was based on the concept of the heart being a pump. Its ability to adequately fill during diastole, and pump blood around the body during systole is a basic, but an essential task required to enable the transport of oxygen and nutrients, while also facilitating the removal of waste products. Over the last few decades, novel advancements have identified multiple additional mechanisms that are interlinked with the cardiovascular system and contribute to the overall cardiac performance, such as neurohormonal activation, nervous system stimulation, interaction with renal function and pulmonary coupling.1 Nevertheless, recent reappraisal of the heart as a mechanical pump is supported by the technological development and implementation of non-invasive approaches to better assess cardiac haemodynamic properties, especially in the context of heart failure (HF).2 The interest comes from the unique opportunity provided by left ventricle (LV) haemodynamic studies that characterize the intrinsic properties of the cardiac muscle. Extracellular matrix and myocyte characteristics, chamber geometry and architecture are the main elements determining the performance of the heart as a pump. In 1895, Otto Frank pioneered the use of pressure–volume (PV) loops to assess haemodynamic properties of the LV.3 This method was implemented for invasive in vivo studies4 and recently extrapolated to develop a simplified approach fully relying on echocardiography and non-invasive pressure assessment.5 Pressure–volume loop analysis traditionally utilizes an invasive haemodynamic assessment and requires specific protocols, including modulation of pre-load, to assess LV properties throughout multiple loops reconstruction.2 Single beat analysis has been developed and validated to simplify this method. More recently, a derivative approach, based on echocardiographic volumes and peripheral non-invasive pressure measurements, turned the PV loop analysis into a more accessible tool. Despite substantial differences and necessary approximations, invasive and non-invasive approaches are based on the same key elements.6 The normal LV PV loop geometry has a rectangular or trapezoidal shape representing all phases of the cardiac cycle (Figure 1). The end-systolic (ESPVR) and end-diastolic PV relationship (EDPVR) are a linear and non-linear relationships, respectively, defining the ranges of LV pressure and volume at different pre-loading conditions. The slope of ESPVR (Ees) is the peak chamber elastance reflecting the mechanical properties of the ventricle when the muscle is in a state of maximal activation. Ees is relatively load-independent and is modified by drugs effecting inotropy, sympathetic stimulation and conditions affecting myocyte integrity. The EDPVR reflects the LV passive mechanical properties and is non-linear due to the interplay between the different components of myocardial fibers (elastin, titin molecules, collagen and amyloid) at different given volumes. Expansion of the extracellular matrix with fibrosis, oedema, myocyte remodelling or amyloidosis increases LV chamber stiffness (with a leftward shift of EDPVR slope, dP/dV). When the stiffness increases, LV compliance (the mathematical inverse of stiffness, dV/dP) diminishes. To further simplify LV assessment, two numerical indexes have been proposed. V120 (the LV volume at which the end-systolic pressure is 120 mmHg) reflects contractility, with high values consistent with reduced contractility and vice versa. V30 (the LV volume at which the end-diastolic pressure is 30 mmHg) is an index of compliance that typically decreases in restrictive and hypertrophic cardiomyopathies (i.e. small ventricles with high pressures). Moving to LV mechanics, the area defined by ESPVR and EDPVR (PVA) represents the total LV mechanical energy per beat. This is the sum of stroke work (SW), the area within the PV loop, representing the energy required to propel blood across vasculature, and the residual potential energy stored in the myocardium at the end of contraction, not dissipated as external SW. PVA correlates linearly with myocardial oxygen consumption per beat and can be calculated as a function of LV end-diastolic pressure, being an index of diastolic and systolic function, it strongly correlates with stroke volume (SV). The PVAiso can be constructed by plotting the PVA values at each LV pressure, and PVAiso30 (the value indexed to a LV end-diastolic pressure of 30 mmHg) is obtained as an index of systo-diastolic function. Although these parameters are less accessible than traditional markers of systolic function, they represent a valuable tool to further define myocardial mechanical properties using a haemodynamic-based assessment. As simplified in Figure 1, the PV loops in HF with reduced (HFrEF) and preserved ejection fraction (HFpEF) nicely diverge, and the therapeutic effects of common treatments can be easily visualized. Cardiac amyloidosis, traditionally classified within the HFpEF category,7 is an exemplar infiltrative myocardial disease. Cardiac amyloidosis shares with HFpEF the impairment of LV relaxation and compliance, resulting in a left and upright shift of EDPVR that is associated with (at least in the earliest stages) preserved ESPVR. This typically leads to a reduced SV, especially during physical exertion, despite the presence of a normal or mildly reduced ejection fraction. Drugs targeting the amyloid production are expected to slow the impairment of LV compliance, whilst drugs directly targeting the deposits are expected to eventually lead to a reversion towards normality. In this issue of the Journal, Rosenblum et al.8 used non-invasive PV techniques to delineate the effect of patisiran on LV mechanics in the pre-specified cardiac population of the APOLLO trial. The study augments an understanding of the mechanistic effects of patisiran treatment on LV function in transthyretin amyloid (ATTR) cardiomyopathy, and refines insights into cardiac treatment response. The study population included 126 patients with evidence of cardiac involvement, defined as a baseline LV wall thickness ≥13 mm and no history of aortic valve disease or hypertension. A total of 90 (71%) participants received patisiran and 36 (29%) patients received placebo. The authors found reduced SV decline in subjects receiving patisiran as compared to placebo as early as 9 months, with a least square mean change in SV of −0.3 ± 1.2 ml for patisiran and − 5.4 ± 1.9 ml for placebo (p = 0.021) at 9 months. Using the PV loop techniques, the authors demonstrated that these changes were associated with a reduced loss of LV compliance (evidenced by the V30 reduction, reflecting an upper and leftward shift of EDPVR) in the treated patients as compared to placebo. These observations are likely to reflect reduced disease progression in treated patients compared to placebo, driven by diminished ATTR fibril production and subsequent deposition within the myocardium, and reduced worsening of the myocardial stiffness. The authors also found a reduction in the progression of PVAiso30, in the treated group, as compared to placebo, likely reflecting a reduction in the loss of LV efficiency and failure to maintain adequate filling. Taken together these results elucidate the changes in myocardial mechanics with patisiran treatment compared to placebo, demonstrating the central role of changes in chamber compliance. The changes between treated patients and the placebo group were detected as early as 9 months, before changes in other traditional structural and functional echocardiographic biomarkers, including deformation and non-deformation-based parameters, highlighting the potential role of PV loop analysis as a sensitive technique to assess early response to treatment. There are a number of limitations that need to be considered when drawing conclusions from this study. Firstly, as acknowledged by the investigators, the pre-specified cardiac subpopulation of the APOLLO study was defined as those with baseline LV wall thickness >13 mm and no history of aortic valve disease or hypertension. This is a sensitive but poorly specific approach to define cardiac amyloidosis. Secondly, these patients have a predominant polyneuropathic presentation. Typically, patients with a polyneuropathic presentation have a minor degree of cardiac involvement compared to patients with a cardiomyopathic presentation. This is confirmed by relatively low N-terminal pro-B-type natriuretic peptide levels as well as structural and functional changes on echocardiography. As a consequence, the usefulness of this approach remains to be demonstrated in more advanced infiltration, which is typically the case in patients with ATTR cardiomyopathy. However, it seems reasonable to expect PV loops to demonstrate utility in defining LV compliance reduction or loss of mechanical energy in more advanced stages of infiltration, as this is typically seen in HFrEF. Thirdly, the non-invasive PV loop approach relies on several approximations related to the intrinsic limits of echocardiography in estimating LV end-diastolic pressures and also relies on limited validation against invasive measurements, especially in infiltrative cardiac disease. Lastly, albeit intriguing and very informative from a pathophysiological perspective, the method used by the authors is complex, and therefore challenging to conduct in the clinical setting. The PV loop analysis is not as easily accessible as more conventional measures of cardiac function, and its reproducibility in this population is yet to be verified. In conclusion, the authors should be commended for having expanded the use of non-invasive PV loop analysis and having enriched our understanding of the changes in myocardial mechanics that occur with treatment in ATTR cardiomyopathy. It is probably too early to fully establish the independent value of these parameters over and above more traditional echocardiographic indices, and future studies focusing on the relationship between the effects of treatment on chamber function and mortality will be key to fully assess the role of these measurements. Nevertheless, this approach should be used in future studies to continue to explore the role of these biomarkers in tracking treatment response in patients with cardiac amyloidosis.
No takes yet. Share an insight, caveat, or question.
Fontana et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: